The personalized genomics market size has grown rapidly in recent years. It will grow from $9.45 billion in 2025 to $10.96 billion in 2026 at a compound annual growth rate (CAGR) of 16%. The growth in the historic period can be attributed to declining costs of genetic sequencing, increasing prevalence of chronic and genetic diseases, growth in research-based genomics studies, expansion of diagnostic laboratory infrastructure, early adoption of precision medicine approaches.
The personalized genomics market size is expected to see rapid growth in the next few years. It will grow to $19.61 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to integration of genomics into routine clinical practice, rising demand for personalized medicine, advancements in sequencing technologies, expansion of wellness and ancestry testing, growing investments by pharmaceutical and biotechnology companies. Major trends in the forecast period include rising adoption of direct-to-consumer genetic testing, growing use of pharmacogenomics in treatment planning, increasing demand for preventive and predictive healthcare, expansion of genetic testing in reproductive health, rising consumer awareness of lifestyle and wellness genomics.
The increasing prevalence of chronic diseases is anticipated to drive the growth of the personalized genomics market in the coming years. Chronic diseases are long-term health conditions that require continuous management and include diabetes, cardiovascular diseases, hypertension, and other complex disorders. The rise in chronic diseases is mainly attributed to aging populations, sedentary lifestyles, unhealthy dietary patterns, and environmental influences that contribute to the simultaneous development of multiple conditions. Personalized genomics aids chronic disease management by enabling large-scale genotyping and sequencing to categorize individuals based on genetic risk, supporting more accurate diagnoses, targeted treatments, and improved preventive strategies. For instance, in April 2025, according to the U.S. Centers for Disease Control and Prevention (CDC), a US-based organization, 76.4% of U.S. adults - approximately 194 million people - had at least one of 12 selected chronic conditions, while 51.4% (around 130 million individuals) were living with two or more of these conditions. Therefore, the rising prevalence of chronic diseases is fueling the growth of the personalized genomics market.
Major companies operating in the personalized genomics market are concentrating on the development of innovative solutions, such as personalized genomics platforms, to deliver customized insights related to health, wellness, and disease prevention. A personalized genomics platform is a system designed to analyze an individual’s genetic information and provide tailored recommendations and insights concerning health status, wellness optimization, and disease risk. For example, in September 2024, Neuberg Diagnostics Private Limited, an India-based diagnostic services company, launched Geniee Decode Your DNA, a customized genomics platform. This personalized genomics platform delivers individualized health, nutrition, and medication insights based on a person’s genetic profile, helping to optimize wellness, prevent disease, and personalize treatments for improved health outcomes.
In August 2024, Labcorp, a US-based diagnostics and laboratory services company, acquired selected assets of Invitae Corporation for an undisclosed amount. Through this acquisition, Labcorp seeks to enhance its specialty testing portfolio and strengthen the use of genetic data to advance clinical trials and personalized care in oncology and rare disease areas. Invitae Corporation is a US-based medical genetics company specializing in comprehensive genetic testing and genomic data services.
Major companies operating in the personalized genomics market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation.
North America was the largest region in the personalized genomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized genomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the personalized genomics market by increasing costs for imported sequencing instruments, reagents, and testing consumables, impacting overall test pricing. Sequencing-based tests and advanced molecular technologies are most affected, particularly in regions dependent on imports such as Asia-Pacific and parts of Europe. These cost pressures can slow adoption in diagnostics and wellness applications. However, tariffs are also encouraging domestic manufacturing, local innovation, and regional capacity building for genomics technologies.
The personalized genomics market research report is one of a series of new reports that provides personalized genomics market statistics, including personalized genomics industry global market size, regional shares, competitors with a personalized genomics market share, detailed personalized genomics market segments, market trends and opportunities, and any further data you may need to thrive in the personalized genomics industry. This personalized genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Personalized genomics refers to the application of an individual’s genetic data to customize medical care, lifestyle guidance, and disease risk evaluations based on their unique DNA makeup. It is used in areas such as predicting disease susceptibility, optimizing drug response, and supporting preventive healthcare approaches.
The main test types in personalized genomics include oncology testing, infectious disease testing, neurological testing, cardiovascular testing, and other categories. Oncology testing comprises diagnostic procedures used to detect, diagnose, and monitor cancer through genetic, molecular, and imaging techniques. The technologies utilized in oncology testing include polymerase chain reaction (PCR)-based tests, microarray-based assays, sequencing-based tests, and other advanced methods. These tests are applied across areas such as diagnostics, precision medicine, wellness, reproductive health, sports nutrition, lifestyle management, and others, and they serve end users including hospitals, clinics, research institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, and other organizations.
The personalized genomics market consists of revenues earned by entities by providing services such as pharmacogenomic services, genetic counseling, and customized fitness plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized genomics market also includes sales of genetic testing kits, health risk assessments, and nutrigenomics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The personalized genomics market size is expected to see rapid growth in the next few years. It will grow to $19.61 billion in 2030 at a compound annual growth rate (CAGR) of 15.7%. The growth in the forecast period can be attributed to integration of genomics into routine clinical practice, rising demand for personalized medicine, advancements in sequencing technologies, expansion of wellness and ancestry testing, growing investments by pharmaceutical and biotechnology companies. Major trends in the forecast period include rising adoption of direct-to-consumer genetic testing, growing use of pharmacogenomics in treatment planning, increasing demand for preventive and predictive healthcare, expansion of genetic testing in reproductive health, rising consumer awareness of lifestyle and wellness genomics.
The increasing prevalence of chronic diseases is anticipated to drive the growth of the personalized genomics market in the coming years. Chronic diseases are long-term health conditions that require continuous management and include diabetes, cardiovascular diseases, hypertension, and other complex disorders. The rise in chronic diseases is mainly attributed to aging populations, sedentary lifestyles, unhealthy dietary patterns, and environmental influences that contribute to the simultaneous development of multiple conditions. Personalized genomics aids chronic disease management by enabling large-scale genotyping and sequencing to categorize individuals based on genetic risk, supporting more accurate diagnoses, targeted treatments, and improved preventive strategies. For instance, in April 2025, according to the U.S. Centers for Disease Control and Prevention (CDC), a US-based organization, 76.4% of U.S. adults - approximately 194 million people - had at least one of 12 selected chronic conditions, while 51.4% (around 130 million individuals) were living with two or more of these conditions. Therefore, the rising prevalence of chronic diseases is fueling the growth of the personalized genomics market.
Major companies operating in the personalized genomics market are concentrating on the development of innovative solutions, such as personalized genomics platforms, to deliver customized insights related to health, wellness, and disease prevention. A personalized genomics platform is a system designed to analyze an individual’s genetic information and provide tailored recommendations and insights concerning health status, wellness optimization, and disease risk. For example, in September 2024, Neuberg Diagnostics Private Limited, an India-based diagnostic services company, launched Geniee Decode Your DNA, a customized genomics platform. This personalized genomics platform delivers individualized health, nutrition, and medication insights based on a person’s genetic profile, helping to optimize wellness, prevent disease, and personalize treatments for improved health outcomes.
In August 2024, Labcorp, a US-based diagnostics and laboratory services company, acquired selected assets of Invitae Corporation for an undisclosed amount. Through this acquisition, Labcorp seeks to enhance its specialty testing portfolio and strengthen the use of genetic data to advance clinical trials and personalized care in oncology and rare disease areas. Invitae Corporation is a US-based medical genetics company specializing in comprehensive genetic testing and genomic data services.
Major companies operating in the personalized genomics market are Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., GeneDx LLC, Ancestry Inc., Oxford Nanopore Technologies plc, Genomic Health Inc., 23andMe Holding Co., Color Health Inc., Helix OpCo LLC, Personalis Inc., Dante Genomics, Gene By Gene Ltd., Veritas Genetics Inc., Futura Genetics, Nebula Genomics Inc., Pathway Genomics Corporation.
North America was the largest region in the personalized genomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized genomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the personalized genomics market by increasing costs for imported sequencing instruments, reagents, and testing consumables, impacting overall test pricing. Sequencing-based tests and advanced molecular technologies are most affected, particularly in regions dependent on imports such as Asia-Pacific and parts of Europe. These cost pressures can slow adoption in diagnostics and wellness applications. However, tariffs are also encouraging domestic manufacturing, local innovation, and regional capacity building for genomics technologies.
The personalized genomics market research report is one of a series of new reports that provides personalized genomics market statistics, including personalized genomics industry global market size, regional shares, competitors with a personalized genomics market share, detailed personalized genomics market segments, market trends and opportunities, and any further data you may need to thrive in the personalized genomics industry. This personalized genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Personalized genomics refers to the application of an individual’s genetic data to customize medical care, lifestyle guidance, and disease risk evaluations based on their unique DNA makeup. It is used in areas such as predicting disease susceptibility, optimizing drug response, and supporting preventive healthcare approaches.
The main test types in personalized genomics include oncology testing, infectious disease testing, neurological testing, cardiovascular testing, and other categories. Oncology testing comprises diagnostic procedures used to detect, diagnose, and monitor cancer through genetic, molecular, and imaging techniques. The technologies utilized in oncology testing include polymerase chain reaction (PCR)-based tests, microarray-based assays, sequencing-based tests, and other advanced methods. These tests are applied across areas such as diagnostics, precision medicine, wellness, reproductive health, sports nutrition, lifestyle management, and others, and they serve end users including hospitals, clinics, research institutions, pharmaceutical and biotechnology companies, diagnostic laboratories, and other organizations.
The personalized genomics market consists of revenues earned by entities by providing services such as pharmacogenomic services, genetic counseling, and customized fitness plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized genomics market also includes sales of genetic testing kits, health risk assessments, and nutrigenomics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Personalized Genomics Market Characteristics
3. Personalized Genomics Market Supply Chain Analysis
4. Global Personalized Genomics Market Trends and Strategies
5. Personalized Genomics Market Analysis of End Use Industries
7. Global Personalized Genomics Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Personalized Genomics Total Addressable Market (TAM) Analysis for the Market
9. Personalized Genomics Market Segmentation
10. Personalized Genomics Market Regional and Country Analysis
11. Asia-Pacific Personalized Genomics Market
12. China Personalized Genomics Market
13. India Personalized Genomics Market
14. Japan Personalized Genomics Market
15. Australia Personalized Genomics Market
16. Indonesia Personalized Genomics Market
17. South Korea Personalized Genomics Market
18. Taiwan Personalized Genomics Market
19. South East Asia Personalized Genomics Market
20. Western Europe Personalized Genomics Market
21. UK Personalized Genomics Market
22. Germany Personalized Genomics Market
23. France Personalized Genomics Market
24. Italy Personalized Genomics Market
25. Spain Personalized Genomics Market
26. Eastern Europe Personalized Genomics Market
27. Russia Personalized Genomics Market
28. North America Personalized Genomics Market
29. USA Personalized Genomics Market
30. Canada Personalized Genomics Market
31. South America Personalized Genomics Market
32. Brazil Personalized Genomics Market
33. Middle East Personalized Genomics Market
34. Africa Personalized Genomics Market
36. Personalized Genomics Market Competitive Landscape and Company Profiles
37. Personalized Genomics Market Other Major and Innovative Companies
40. Personalized Genomics Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Personalized Genomics Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses personalized genomics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for personalized genomics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The personalized genomics market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: Oncology Testing; Neurological Testing; Cardiovascular Testing; Other Test Types2) By Technology: Polymerase Chain Reaction-Based Tests; Microarray-Based Tests; Sequencing-Based Tests; Other Technologies
3) By Application: Diagnostics; Precision Medicine; Wellness; Reproductive Health; Sports Nutrition And Health; Lifestyle; Other Applications
4) By End User: Hospitals And Clinics; Research Centers; Pharmaceutical And Biotechnology Companies; Diagnostic Laboratories; Other End Users
Subsegments:
1) By Oncology Testing: Liquid Biopsy; Tumor Profiling; Genetic Testing For Cancer Risk; Companion Diagnostics2) By Neurological Testing: Alzheimer's Disease Testing; Huntington’s Disease Testing; Parkinson's Disease Testing; Epilepsy Testing
3) By Cardiovascular Testing: Genetic Risk for Cardiovascular Diseases; Arrhythmia Testing; Coronary Artery Disease Testing
4) By Other Test Types: Pharmacogenomics Testing; Genetic Screening For Inherited Disorders; Ancestry Testing
Companies Mentioned: Thermo Fisher Scientific Inc.; Illumina Inc.; Myriad Genetics Inc.; BGI Genomics Co. Ltd.; Invitae Corporation; Guardant Health Inc.; GeneDx LLC; Ancestry Inc.; Oxford Nanopore Technologies plc; Genomic Health Inc.; 23andMe Holding Co.; Color Health Inc.; Helix OpCo LLC; Personalis Inc.; Dante Genomics; Gene By Gene Ltd.; Veritas Genetics Inc.; Futura Genetics; Nebula Genomics Inc.; Pathway Genomics Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Personalized Genomics market report include:- Thermo Fisher Scientific Inc.
- Illumina Inc.
- Myriad Genetics Inc.
- BGI Genomics Co. Ltd.
- Invitae Corporation
- Guardant Health Inc.
- GeneDx LLC
- Ancestry Inc.
- Oxford Nanopore Technologies plc
- Genomic Health Inc.
- 23andMe Holding Co.
- Color Health Inc.
- Helix OpCo LLC
- Personalis Inc.
- Dante Genomics
- Gene By Gene Ltd.
- Veritas Genetics Inc.
- Futura Genetics
- Nebula Genomics Inc.
- Pathway Genomics Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 10.96 Billion |
| Forecasted Market Value ( USD | $ 19.61 Billion |
| Compound Annual Growth Rate | 15.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
